explore -WSS

explore

author：explore 2025-10-03 00:06:53 - browse：3

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Pregnancy discrimination could be enabled by AI

focus

hotspot

WSS

Addiction doctors spar with methadone clinics over legislation

Scientists successfully use ultrasound imaging to map brain activity

Teach medical students about patients with intellectual disabilities

AI used to predict Covid

Pharma patents targeted by Biden in move to slash drug prices

What will save rural psychiatry services? Higher Medicaid payments

hotspot

explore

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

iTeos Therapeutics debuts first data on TIGIT

Novavax promises a turnaround & Lilly roils the obesity market

Addiction doctors spar with methadone clinics over legislation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What will save rural psychiatry services? Higher Medicaid payments

Cancer drug shortages should be causing more outrage

Pregnancy discrimination could be enabled by AI

In Memoriam: Notable people who died in 2023

Startling documents reveal new facets of Sacklers' opioid empire

hotspot

In diabetes hearing, Sanders takes on a new foe: food makers

Why sickle cell disease is getting the first CRISPR treatment

FDA needs staff influx to meet gene therapy needs, Marks says

AI models in health care face new federal disclosure requirements

Health insurers say they are turning to AI to cut costs, improve care

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

focus

leisure time

hotspot

Wikipedia